MedTrace Logo

Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

NCT07396337 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2026-02-09

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of QHRD106 injection in treating acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

QHRD106 Injection (Low-dose group)

Participants will receive QHRD106 injection (5600 IU) every 7 days with a total of 3 doses.

DRUG

QHRD106 Injection (Middle-dose group)

Participants will receive QHRD106 injection (8400 IU) every 7 days with a total of 3 doses.

DRUG

QHRD106 Injection (High-dose group)

Participants will receive QHRD106 injection (12600 IU) every 7 days with a total of 3 doses.

DRUG

Placebo

Participants will receive placebo every 7 days with a total of 3 doses.

Sponsors & Collaborators

  • Changzhou Qianhong Bio-pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yun Xu, professor · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-19
Primary Completion
2026-10-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07396337 on ClinicalTrials.gov